{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:06:36Z","timestamp":1793307996207,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recently emerged Omicron (B.1.1.529) variant has rapidly surpassed Delta to become the predominant circulating SARS-CoV-2 variant, given the higher transmissibility rate and immune escape ability, resulting in breakthrough infections in vaccinated individuals. A new generation of SARS-CoV-2 vaccines targeting the Omicron variant are urgently needed. Here, we developed a subunit vaccine named RBD-HR\/trimer by directly linking the sequence of RBD derived from the Delta variant (containing L452R and T478K) and HR1 and HR2 in SARS-CoV-2 S2 subunit in a tandem manner, which can self-assemble into a trimer. In multiple animal models, vaccination of RBD-HR\/trimer formulated with MF59-like oil-in-water adjuvant elicited sustained humoral immune response with high levels of broad-spectrum neutralizing antibodies against Omicron variants, also inducing a strong T cell immune response in vivo. In addition, our RBD-HR\/trimer vaccine showed a strong boosting effect against Omicron variants after two doses of mRNA vaccines, featuring its capacity to be used in a prime-boost regimen. In mice and non-human primates, RBD-HR\/trimer vaccination could confer a complete protection against live virus challenge of Omicron and Delta variants. The results qualified RBD-HR\/trimer vaccine as a promising next-generation vaccine candidate for prevention of SARS-CoV-2, which deserved further evaluation in clinical trials.<\/jats:p>","DOI":"10.1038\/s41467-022-33209-9","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T11:05:40Z","timestamp":1663412740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant"],"prefix":"10.1038","volume":"13","author":[{"given":"Cai","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-2301","authenticated-orcid":false,"given":"Weiqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqu","family":"Alu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfei","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-6204","authenticated-orcid":false,"given":"Guowen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1895","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0364-8948","authenticated-orcid":false,"given":"Zhenling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-1721","authenticated-orcid":false,"given":"Zhaoming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-0614","authenticated-orcid":false,"given":"Yoshimasa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-9735","authenticated-orcid":false,"given":"Shuaiyao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9592-9554","authenticated-orcid":false,"given":"Xiaozhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-592X","authenticated-orcid":false,"given":"Guangwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-6422","authenticated-orcid":false,"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"33209_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"33209_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693\u2013699 (2022).","journal-title":"Nature"},{"key":"33209_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13054-021-03662-x","volume":"25","author":"J Khateeb","year":"2021","unstructured":"Khateeb, J., Li, Y. & Zhang, H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit. Care 25, 244 (2021).","journal-title":"Crit. Care"},{"key":"33209_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"33209_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2022","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2022).","journal-title":"Nature"},{"key":"33209_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"33209_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","volume":"399","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234\u2013236 (2022).","journal-title":"Lancet"},{"key":"33209_CR8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33209_CR9","doi-asserted-by":"publisher","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","volume":"376","author":"JRC Pulliam","year":"2022","unstructured":"Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 376, eabn4947 (2022).","journal-title":"Science"},{"key":"33209_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185, 447\u2013456.e411 (2022).","journal-title":"Cell"},{"key":"33209_CR11","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.xcrm.2022.100529","volume":"3","author":"VV Edara","year":"2022","unstructured":"Edara, V. V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep. Med. 3, 100529 (2022).","journal-title":"Cell Rep. Med."},{"key":"33209_CR12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678\u2013680 (2022).","journal-title":"Science"},{"key":"33209_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMc2119912","volume":"386","author":"R Pajon","year":"2022","unstructured":"Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088\u20131091 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33209_CR14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","volume":"185","author":"M Gagne","year":"2022","unstructured":"Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185, 1556\u20131571.e1518 (2022).","journal-title":"Cell"},{"key":"33209_CR15","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728\u20131744.e1716 (2022).","journal-title":"Cell"},{"key":"33209_CR16","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.cell.2022.03.037","volume":"185","author":"B Ying","year":"2022","unstructured":"Ying, B. et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell 185, 1572\u20131587.e1511 (2022).","journal-title":"Cell"},{"key":"33209_CR17","doi-asserted-by":"publisher","unstructured":"Tubiana, J. et al. Reduced antigenicity of Omicron lowers host serologic response. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.02.15.480546 (2022).","DOI":"10.1101\/2022.02.15.480546"},{"key":"33209_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572\u2013577 (2020).","journal-title":"Nature"},{"key":"33209_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733.e711 (2020).","journal-title":"Cell"},{"key":"33209_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382.e1317 (2020).","journal-title":"Cell"},{"key":"33209_CR21","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1016\/j.vaccine.2020.09.058","volume":"38","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine 38, 7205\u20137212 (2020).","journal-title":"Vaccine"},{"key":"33209_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","volume":"53","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315\u20131330.e1319 (2020).","journal-title":"Immunity"},{"key":"33209_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41392-021-00750-w","volume":"6","author":"W Sun","year":"2021","unstructured":"Sun, W. et al. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct. Target. Ther. 6, 340 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"33209_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21634-1","volume":"12","author":"JG Liang","year":"2021","unstructured":"Liang, J. G. et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat. Commun. 12, 1346 (2021).","journal-title":"Nat. Commun."},{"key":"33209_CR25","doi-asserted-by":"publisher","first-page":"22596","DOI":"10.1074\/jbc.M501155200","volume":"280","author":"EK Thomas","year":"2005","unstructured":"Thomas, E. K. et al. Endo180 binds to the C-terminal region of type I collagen. J. Biol. Chem. 280, 22596\u201322605 (2005).","journal-title":"J. Biol. Chem."},{"key":"33209_CR26","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/22221751.2020.1770631","volume":"9","author":"H Sun","year":"2020","unstructured":"Sun, H. et al. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerg. Microbes Infect. 9, 1238\u20131241 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"33209_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343\u2013355 (2020).","journal-title":"Cell Res."},{"key":"33209_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/btpr.1842","volume":"30","author":"A Contreras-G\u00f3mez","year":"2014","unstructured":"Contreras-G\u00f3mez, A., S\u00e1nchez-Mir\u00f3n, A., Garc\u00eda-Camacho, F., Molina-Grima, E. & Chisti, Y. Protein production using the baculovirus-insect cell expression system. Biotechnol. Prog. 30, 1\u201318 (2014).","journal-title":"Biotechnol. Prog."},{"key":"33209_CR29","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jip.2011.05.003","volume":"107","author":"MM Cox","year":"2011","unstructured":"Cox, M. M. & Hashimoto, Y. A fast track influenza virus vaccine produced in insect cells. J. Invertebr. Pathol. 107, S31\u2013S41 (2011).","journal-title":"J. Invertebr. Pathol."},{"key":"33209_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"33209_CR31","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819\u20131829 (2021).","journal-title":"Lancet"},{"key":"33209_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33209_CR33","first-page":"181","volume":"4","author":"BA Jameson","year":"1988","unstructured":"Jameson, B. A. & Wolf, H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput. Appl. Biosci. 4, 181\u2013186 (1988).","journal-title":"Comput. Appl. Biosci."},{"key":"33209_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10529-022-03238-x","volume":"44","author":"CRC Calado","year":"2022","unstructured":"Calado, C. R. C. Antigenic and conserved peptides from diverse Helicobacter pylori antigens. Biotechnol. Lett. 44, 535\u2013545 (2022).","journal-title":"Biotechnol. Lett."},{"key":"33209_CR35","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"33209_CR36","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"33209_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-021-00657-1","volume":"22","author":"BJ Laidlaw","year":"2022","unstructured":"Laidlaw, B. J. & Ellebedy, A. H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7\u201318 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"33209_CR38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","volume":"185","author":"PA Mudd","year":"2022","unstructured":"Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603\u2013613.e615 (2022).","journal-title":"Cell"},{"key":"33209_CR39","doi-asserted-by":"publisher","first-page":"105253","DOI":"10.1016\/j.antiviral.2022.105253","volume":"198","author":"R Abdelnabi","year":"2022","unstructured":"Abdelnabi, R. et al. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antivir. Res. 198, 105253 (2022).","journal-title":"Antivir. Res."},{"key":"33209_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","volume":"602","author":"E Cameroni","year":"2022","unstructured":"Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664\u2013670 (2022).","journal-title":"Nature"},{"key":"33209_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).","journal-title":"Nat. Commun."},{"key":"33209_CR42","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1128\/JVI.02433-13","volume":"87","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J. Virol. 87, 13134\u201313140 (2013).","journal-title":"J. Virol."},{"key":"33209_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2022","unstructured":"Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. 386, 492\u2013494 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33209_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mco2.72","volume":"2","author":"C He","year":"2021","unstructured":"He, C. et al. A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. MedComm 2, 430\u2013441 (2021).","journal-title":"MedComm"},{"key":"33209_CR45","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1093\/infdis\/jiab635","volume":"225","author":"MT Laurie","year":"2022","unstructured":"Laurie, M. T. et al. SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including delta and omicron. J. Infect. Dis. 225, 1909\u20131914 (2022).","journal-title":"J. Infect. Dis."},{"key":"33209_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"33209_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41392-022-00980-6","volume":"7","author":"C He","year":"2022","unstructured":"He, C. et al. Spike protein of SARS-CoV-2 Omicron (B.1.1.529) variant has a reduced ability to induce the immune response. Signal Transduct. Target. Ther. 7, 119 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"33209_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-022-00914-2","volume":"7","author":"S Lin","year":"2022","unstructured":"Lin, S. et al. Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding. Signal Transduct. Target. Ther. 7, 56 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"33209_CR49","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","volume":"607","author":"RK Suryawanshi","year":"2022","unstructured":"Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature 607, 351\u2013355 (2022).","journal-title":"Nature"},{"key":"33209_CR50","doi-asserted-by":"crossref","unstructured":"Ravichandran, S. et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci. Transl. Med. 12, eabc3539 (2020).","DOI":"10.1126\/scitranslmed.abc3539"},{"key":"33209_CR51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41392-021-00756-4","volume":"6","author":"F Ye","year":"2021","unstructured":"Ye, F. et al. S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. Signal Transduct. Target Ther. 6, 343 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"33209_CR52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"33209_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsb.2006.05.009","volume":"157","author":"G Tang","year":"2007","unstructured":"Tang, G. et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38\u201346 (2007).","journal-title":"J. Struct. Biol."},{"key":"33209_CR54","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1042\/BCJ20210708","volume":"478","author":"D Kimanius","year":"2021","unstructured":"Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools for automated cryo-EM single-particle analysis in RELION-4.0. Biochem. J. 478, 4169\u20134185 (2021).","journal-title":"Biochem. J."},{"key":"33209_CR55","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"33209_CR56","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","volume":"14","author":"EJ Ko","year":"2018","unstructured":"Ko, E. J. & Kang, S. M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum. Vaccin Immunother. 14, 3041\u20133045 (2018).","journal-title":"Hum. Vaccin Immunother."},{"key":"33209_CR57","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jconrel.2021.05.024","volume":"335","author":"H Huang","year":"2021","unstructured":"Huang, H. et al. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2. J. Controlled Release. 335, 449\u2013456 (2021).","journal-title":"J. Controlled Release."},{"key":"33209_CR58","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33209-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33209-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33209-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T15:05:00Z","timestamp":1663427100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33209-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33209"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33209-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by the WestVac Biopharma Co. Ltd. Jiong Li, W.W., G.S., Z.Z., L.Y., Jingyun Yang, Jinliang Yang, Z.W., Y.W., G.L. and X.W. are also working at the WestVac Biopharma Co. Ltd. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5459"}}